1-4 of 4
Karen A. Kurdziel, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4527.
https://doi.org/10.1182/blood.V128.22.4527.4527
Published: 2016
Journal Articles

Longitudinal 18 f-FDG-PET-CT Analysis in Newly Diagnosed Multiple Myeloma (NDMM) Patients Following Carfilzomib, Lenalidomide, Dexamethasone Induction and Lenalidomide Maintenance (CRd-R)

Neha S Korde, MD, Dickran Kazandjian, MD, Mark Roschewski, MD, Sham Mailankody, MD, Malin Hultcrantz, MD, PhD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Peter Choyke, MD, Hani Hassoun, MD, Alexander M. Lesokhin, MD, Nikoletta Lendvai, MDPhD, Eric L. Smith, MD PhD, Ola Landgren, MDPhD, Karen A. Kurdziel, MD, Maria Liza Lindenberg, MD
Journal: Blood
Blood (2016) 128 (22): 3274.
https://doi.org/10.1182/blood.V128.22.3274.3274
Published: 2016
Journal Articles

Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3339.
https://doi.org/10.1182/blood.V128.22.3339.3339
Published: 2016
Journal Articles

Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation

Nancy M. Hardy, MD, Deborah Citrin, MD, Frances T. Hakim, PhD, Daniele N. Avila, CRNP, Bazetta Blacklock-Schuver, RN, Stephanie Cotton, RN, Monica Cho, Daniel H. Fowler, MD, Juan C. Gea-Banacloche, MD, Noa G. Holtzman, MD, Karen A. Kurdziel, MD, Sarfraz Memon, MD, Steven Z. Pavletic, MD, Stefania Pittaluga, MD PhD, Jeremy J. Rose, BA, Claude Sportes, MD, Jennifer S. Wilder, RN, Ronald E. Gress, MD, Michael R. Bishop, MD
Journal: Blood
Blood (2015) 126 (23): 1962.
https://doi.org/10.1182/blood.V126.23.1962.1962
Published: 2015